The emergence of cefiderocol resistance in 
        Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Nicholas Teran; Stephanie L Egge; Kady Phe; Rodrigo P Baptista; Vincent H Tam; William R Miller

doi:10.1128/aac.01009-23

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Nicholas Teran, Stephanie L Egge, Kady Phe, Rodrigo P Baptista, Vincent H Tam, William R Miller

Research output: Contribution to journal › Article › peer-review

Abstract

Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

Original language	English (US)
Pages (from-to)	e0100923
Journal	Antimicrobial Agents and Chemotherapy
DOIs	https://doi.org/10.1128/aac.01009-23
State	E-pub ahead of print - Dec 8 2023

Access to Document

10.1128/aac.01009-23

Cite this

@article{37990d0907594a49a6121119a6ea6c69,

title = "The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.",

abstract = "Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance. ",

author = "Nicholas Teran and Egge, {Stephanie L} and Kady Phe and Baptista, {Rodrigo P} and Tam, {Vincent H} and Miller, {William R}",

year = "2023",

month = dec,

day = "8",

doi = "10.1128/aac.01009-23",

language = "English (US)",

pages = "e0100923",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

}

TY - JOUR

T1 - The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

AU - Teran, Nicholas

AU - Egge, Stephanie L

AU - Phe, Kady

AU - Baptista, Rodrigo P

AU - Tam, Vincent H

AU - Miller, William R

PY - 2023/12/8

Y1 - 2023/12/8

N2 - Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

AB - Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

U2 - 10.1128/aac.01009-23

DO - 10.1128/aac.01009-23

M3 - Article

C2 - 38063509

SN - 0066-4804

SP - e0100923

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

ER -

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Abstract

Access to Document

Fingerprint

Cite this